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Altered expression of genes involved in
ganglioside biosynthesis in substantia nigra
neurons in Parkinson’s disease
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Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia,
Pennsylvania, United States of America
* jay.schneider@jefferson.edu
Abstract
Reduced expression of GM1 and other major brain gangliosides GD1a, GD1b and GT1b
have been reported in Parkinson’s disease (PD) brain. Mechanisms underlying these
changes are unclear but may be due to a deficit in the ganglioside biosynthetic process. The
present study examined the extent to which deficits in gene expression of key biosynthetic
enzymes involved in synthesis of GM1 and GD1b (B3galt4) and GD1a and GT1b (St3gal2)
exist in neuromelanin-containing neurons in the PD substantia nigra (SN). In situ hybridiza-
tion histochemistry was used to examine gene expression of B3GALT4 and ST3GAL2 in
neuromelanin-containing neurons in the SN in 8 normal controls (61–92 yrs.) and 7 PD sub-
jects (77–95 yrs). There was a significant decrease in both B3GALT4 and ST3GAL2 gene
expression in residual neuromelanin-containing cells in the SN of PD patients compared to
age-matched neurologically normal controls. These changes appeared to be cell-type spe-
cific as abundant B3GALT4 and ST3GAL2 gene expression was observed in non-neurome-
lanin containing neurons located outside of the SN in the PD brain. These data show that
residual neuromelanin-containing neurons in the PD SN have decreased expression of the
ganglioside biosynthetic genes B3GALT4 and ST3GAL2, consistent with previous reports
of decreased levels of gangliosides GM1, GD1a, GD1b and GT1b in the PD SN. These
changes may increase the vulnerability of these neurons to degeneration in response to a
variety of potential stressors.
Introduction
Parkinson’s disease (PD) is a progressive disorder primarily characterized by degeneration of
substantia nigra (SN) dopaminergic neurons with associated loss of dopamine (DA) in the stri-
atum (caudate nucleus and putamen), and accumulation of insoluble protein aggregates (in
Lewy bodies and Lewy neurites), with α-synuclein being the most abundant component [1].
The mechanisms contributing to the onset and progression of PD are not completely known,
but are hypothesized to involve dysfunction of mitochondria, increased oxidative stress result-
ing in multiple forms of oxidative damage, and defects in the ubiquitin-proteasome system
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and lysosomal pathways (leading to an increase in and accumulation of misfolded proteins)
[2, 3].
In addition to the potential disease mechanisms listed above, there has also been recent
interest in the role of lipids in neurodegenerative diseases and in particular, in the pathogenesis
of PD. Abnormalities in the content and composition of various lipids have been reported in
PD brain [ex.,[4–6]]. A recent plasma metabolic profiling study suggested that abnormal meta-
bolic changes in PD plasma were mainly associated with mitochondrial function and lipid
metabolism [7]. Additionally, mutations in the beta-glucosidase gene (GBA) coding for gluco-
cerebrosidase, which breaks down glucosylceramide into glucose and ceramide, have been sug-
gested to be an important risk factor for development of sporadic PD [8].
Of particular interest and functional significance are reported changes in gangliosides in
PD brain, due at least in part to their role in lipid raft structure/function and numerous cell
signaling mechanisms, [9–12]. Gangliosides are sialic acid containing glycosphingolipids, of
which the major species in brain are a- and b-series gangliosides GM1, GD1a, GD1b, and
GT1b [13]. The monosialoganglioside GM1 is of particular interest as it exerts neurotrophic or
neuroprotective effects under a variety of circumstances and influences numerous cellular
activities at the level of plasma and intracellular membranes, where it influences diverse cellu-
lar functions including Ca2+ homeostasis, mitochondrial function, and lysosomal integrity,
among other processes [14–17]. Reduced numbers of GM1 ganglioside-containing cells were
reported in SN pars compacta neurons in brains from PD patients, using FITC-cholera toxin
B histochemistry: only approximately 20% of dopamine neurons in the PD SN expressed GM1
compared to almost 62% in non-PD controls [18]. Reduced expression of GM1, GD1a, and
GD1b were reported in the occipital cortex of PD patients using HPTLC [19]. Using HPTLC,
we have also recently described significant decreases in GD1a, GD1b, and GT1b in SN from
male PD patients, along with a smaller magnitude decrease in GM1 that did not reach statisti-
cal significance [20]. In contrast, we found no significant changes in levels of GM3, GM2, or
GD3 in PD SN. This led us to hypothesize that a potential problem in ganglioside biosynthesis
may exist in the PD SN downstream from GM3, GM2 and GD3 and that a potential change in
expression of key biosynthetic enzymes involved in synthesis of GM1 and GD1b (B3galt4) and
GD1a and GT1b (St3gal2) may exist (the main ganglioside biosynthetic pathways in brain are
shown in Fig 1). Since ganglioside expression is cell type-specific [21], interpretation of poten-
tial gene expression changes such as these in SN homogenates from PD brain could be compli-
cated due to loss of SN neurons, glial responses, and signals from white matter, the current
study was performed to examine B3GALT4 and ST3GAL2 gene expression in neuromelanin-
containing neurons in the SN of PD patients and non-PD controls using in situ hybridization
histochemistry.
Materials and methods
Brain tissues and sectioning
Fully anonymized human brain tissue was obtained through the NIH NeuroBioBank and
sourced from the NICHD Brain and Tissue Bank for Developmental Disorders at the Univer-
sity of Maryland, Baltimore, MD, the Harvard Brain Tissue Resource Center, Belmont, MA,
which is supported in part by HHSN-271-2013-00030C, and from the Human Brain and Spi-
nal Fluid Resource Center, VA West Los Angeles Healthcare Center, 11301 Wilshire Blvd., Los
Angeles, CA, which is sponsored by NINDS/NIMH, the National Multiple Sclerosis Society,
and the Dept. of Veterans Affairs. The clinical diagnosis of Parkinson’s disease was confirmed
at autopsy by presence of gross depigmentation of the SN, microscopic confirmation of SN cell
loss and/or presence of Lewy bodies in the SN, and normal findings in other brain regions
Ganglioside-related gene expression in PD
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Fig 1. Ganglioside biosynthetic pathways. The main gangliosides found in brain are a-series and b-series gangliosides (encircled). Gangliosides are synthesized by
sequential addition of sugars and sialic acid residues onto a sphingosine backbone through the action of various glycosyltransferases (ex., St3gal5, B4galnt1, B3galt4,
St8sia1) and sialyltransferases (St3gal2, St8sia5).
https://doi.org/10.1371/journal.pone.0199189.g001
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sampled. Frozen tissue blocks containing the SN were stored at -80˚C, warmed to -20˚C in a
cryostat, embedded in optimal cutting temperature (OCT) compound, sectioned at 14 μm
thickness and mounted (2 sections/slide) onto Fisherbrand™ Superfrost™ Plus microscope
slides. Slides were kept in the cryostat at -20˚C for 1 hr. to dry, placed in cold slide boxes, and
stored at -80˚C in vacuum-sealed bags until used.
In situ hybridization
In situ hybridization was performed using the RNAscope 2.5 HD Chromogenic Assay kit
(Advanced Cell Diagnostics, Inc.) using a protocol, with slight modifications, as recommended
in the RNAscope 2.5 HD Chromogenic Assay user manual for fresh frozen tissue. Briefly,
slides were removed from the -80˚C freezer and immediately placed in glass Coplin jars con-
taining ice cold 4% paraformaldehyde in PBS and fixed for 2 hrs. at 4˚C. Slides were removed
from the 4% paraformaldehyde and placed in 50% EtOH for 5 min. at room temperature, fol-
lowed by 70% EtOH for 5 min. at room temperature, and then 100% EtOH for 5 min. at room
temperature. Slides were then stored in 100% EtOH overnight at -30˚C. The following day,
slides were removed from the 100% EtOH and allowed to air dry for at least 15 min. A hydro-
phobic barrier was then drawn around each section (Immedge™ pen) and sections were incu-
bated in hydrogen peroxide for 10 min at room temperature, rinsed in dH20, incubated in
RNAscope Protease IV for 30 min at room temperature, and rinsed in PBS. One section on
each slide was then incubated in either a custom human gene-specific RNAscope probe for
B3GALT4 or human ST3GAL2 and the other section was incubated in a positive control probe
(human Cyclophilin B (PPIB)). Some additional slides were also incubated with a negative
control probe (bacterial dapB) to verify the specificity of the assay. Slides were place in a sealed,
humidified tray and incubated for 2 hrs. at 40˚C. After removal of the probes and washes in
RNAscope wash buffer, the sections were sequentially hybridized to a cascade of amplification
molecules, culminating in binding to HRP-labeled probes, followed by signal detection with
Fast Red substrate (RNAscope 2.5 HD Detection Kit-Red, ACB Bio) to detect target RNA.
Slides were then counterstained with Hematoxylin, dried overnight and coverslipped.
Data analysis
All slides were initially evaluated for positive control signal strength at 20x magnification. If
positive control sections had signal of at least 20–30 dots/cell (each dot represents a single
RNA molecule), the tissue was considered to contain RNA of suitable integrity for analysis of
the expression of the target genes. For the purposes of this study, if a dot cluster was visible, it
was counted as one dot. For each gene of interest, the number of dots/cell was counted on
coded slides (to blind the observer to disease status (PD or Control) of the sample) at 20x, with
a range of 20–55 and 20–45 cells analyzed for B3GALT4 expression in control and PD cases,
respectively, and a range of 18–20 and 18–34 cells analyzed for ST3GAL2 expression in control
and PD cases, respectively. To be counted, a cell needed to have an intact hematoxylin-positive
cell body and neuromelanin clearly visible. All dots on a cell were counted; there were no
inclusion or exclusion criteria for selecting a dot to be counted or not counted. Dot count data
from normal control cases and PD cases were then compared using unpaired Student’s t test.
Results
There were no significant differences between the ages or post-mortem intervals (PMI)
between the neurologically normal control subjects and PD subjects (Table 1). All sections
analyzed were from cases with positive control (PPIB) signal of at least 20–30 dots/cell and
with presence of dot clusters, signifying good integrity RNA. Analyses of negative control
Ganglioside-related gene expression in PD
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(dapB) sections showed no signal present and verified lack of non-specific signal in the assay
(S1 Fig).
There was a significant decrease in B3GALT4 expression in residual neuromelanin-contain-
ing cells in the SN of PD patients (7.5 ± 0.9 dots/cell, n = 7) compared to neurologically normal
controls (17.1 ± 1.4 dots/cell, n = 8) (t = 5.293, df = 14, P = 0.0001) (Fig 2A and 2B). Similar to
what was observed for B3GALT4 expression, there was a significant decrease in ST3GAL2
expression in residual neuromelanin-containing cells in the SN of PD patients (6.0 ± 0.4 dots/
cell, n = 7) compared to neurologically normal controls (12.5 ± 1.1 dots/cell, n = 8) (t = 5.532,
df = 14, P< 0.0001) (Fig 3A and 3B). Scatter plots of these data show some overlap in expres-
sion between control and PD groups, with approximately 39% of neuromelanin-containing
neurons in the PD SN within the lower end of the normal range of B3GALT4 expression (Fig
4A). Scatter plots also show some overlap in ST3GAL2 expression between the two groups,
with approximately 50% of neuromelanin-containing neurons in the PD SN showing
ST3GAL2 expression levels within the lower end of the normal range of ST3GAL2 expression
(Fig 4B). The decrease in expression of ST3GAL2 and B3GALT4 in residual dopaminergic
neurons in the PD cases appeared to be specific for this cell type. Abundant ST3GAL2 and
B3GALT4 gene expression was observed in some non-dopaminergic neurons located outside
of the SN in the PD brain, in the same sections in which decreased gene expression was
observed in the SN (Fig 5).
Discussion
The results reported here show for the first time, decreases in gene expression of the glycosyl-
transferase B3GALT4 (GM1/GD1b synthase) and the sialyltransferase ST3GAL2 in neuromela-
nin-containing neurons in the PD SN compared to non-PD controls. These results suggest a
Table 1. Subject characteristics.
Control Age (yrs) PMI (hrs) Sex
1 78 5 M
2 76 16 M
3 78 21 M
4 71 17 M
5 63 23 F
6 88 16 M
7 82 14 M
8 92 15 M
Mean 78.5 ± 3.2 15.9 ± 1.9
PD Age (yrs) PMI (hrs) Sex
1 95 10 M
2 75 5.5 M
3 76 15 M
4 88 21 M
5 77 10 M
6 84 6 F
7 77 22 M
Mean 81.7 ± 2.9 12.8 ± 2.6
PMI = post-mortem interval
https://doi.org/10.1371/journal.pone.0199189.t001
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Fig 2. B3GALT4 gene expression is lower in residual neuromelanin-containing cells in the PD SN than in control
SN neurons. A. In situ hybridization for B3GALT4 gene expression in control (N) and PD substantia nigra (SN). Using
the RNAscope 2.5 HD Detection Kit-Red (ACB Bio), each red dot represents a single RNA molecule. Scale = 25 μm. B.
Counts of the number of dots (RNA molecules) per neuron showed significantly less B3GALT4 RNA in cells in the PD
SN (196 cells analyzed) compared to the control SN (269 cells analyzed). P = 0.0001 compared to Normal.
Neuromelanin appears as brown/black aggregates in cells.
https://doi.org/10.1371/journal.pone.0199189.g002
Ganglioside-related gene expression in PD
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Fig 3. ST3GAL2 gene expression is lower in residual neuromelanin-containing cells in the PD SN than in control
SN neurons. A. In situ hybridization for ST3GAL2 gene expression in control (N) and PD substantia nigra (SN). Using
the RNAscope 2.5 HD Detection Kit-Red (ACB Bio), each red dot represents a single RNA molecule. Scale = 25 μm. B.
Counts of the number of dots (RNA molecules) per neuron showed significantly less ST3GAL2RNA in cells in the PD
SN (218 cells analyzed) compared to the control SN (146 cells analyzed). P< 0.0001 compared to Normal.
Neuromelanin appears as brown/black aggregates in cells.
https://doi.org/10.1371/journal.pone.0199189.g003
Ganglioside-related gene expression in PD
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problem with the ganglioside biosynthetic machinery in remaining dopaminergic neurons in
the PD brain and extend previous findings showing decreased numbers of GM1 ganglioside-
expressing cells in the PD SN [18] and decreased levels of the major brain gangliosides, GM1,
GD1a, GD1b and GT1b in whole SN homogenates from PD patients [20]. Thus, the decreased
expression of B3GALT4 and ST3GAL2 mRNA likely directly underlies the decreased expres-
sion of GM1, GD1a, GD1b and GQ1b observed in PD SN [20], potentially contributing to the
vulnerability of these neurons to neurodegeneration. Since gangliosides are expressed in a cell-
specific manner [21], it is important to study expression of gangliosides and their biosynthetic
processes in specific cells of interest in normal brain and in different disease states in order to
Fig 4. Graphs showing the distribution B3GALT4 (a) and ST3GAL2 (B) gene expression per neuromelanin-
containing neuron in normal and PD substantia nigra (SN). Each dot represents the number of RNA molecules (red
dots counted per cell) counted in each cell sampled. For both genes, there is overlap in the extent to which these genes
are expressed in normal and PD SN neurons.
https://doi.org/10.1371/journal.pone.0199189.g004
Ganglioside-related gene expression in PD
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gain more insight into the role that changes in ganglioside biosynthesis in specific cell types
may play in different neurological diseases.
Gangliosides, sialic acid-containing glycosphingolipids, are integral components of cell
membranes and participate in a wide variety of biological functions (see [16] and [22] for
review). The biosynthesis of gangliosides, including the major brain gangliosides, is a stepwise
process dependent upon the expression and intracellular distribution of glycolsyltransferases
and sialyltransferases (that add carbohydrate groups and sialic acids, respectively). There are 3
main ganglioside branches but only a- and b-series gangliosides are highly expressed in brain.
Due to branch exclusivity, competition between enzymes at key branch points determines the
relative expression levels of the final products. Ganglioside biosynthesis is strictly regulated by
the activities of glycosyltransferases and is controlled at the level of gene transcription and
posttranslational modification, as described in detail previously [23]. GM1/GD1b-synthase is
responsible for the synthesis of GM1/GD1b from GM2/GD2 [23] and these products are sub-
strates of the sialyltransferase St3gal2 [21]. One of the roles for GD1a is to serve as a reserve
pool for the synthesis of GM1, potentially important for helping maintain GM1 at physiologi-
cally relevant levels. Thus, GM1 and GD1a are considered as a functional unit in association
Fig 5. Within a section, some cells located outside of the substantia nigra (SN) showed much higher ST3GAL2 and
B3GALT4 gene expression levels than neuromelanin-containing cells located in the SN in the PD brain. A.
ST3GAL2 gene expression was relatively low in neuromelanin-containing cells in the PD SN (as indicated by the low
number of red dots in cells containing brown/black aggregates indicative of neuromelanin) compared to the level of
ST3GAL2 gene expression that could be observed in neurons in the same section located outside of the SN (B).
Similarly, B3GALT4 gene expression was relatively low in neuromelanin-containing cells in the PD SN (C, as indicated
by the low number of red dots in cells containing brown/black aggregates indicative of neuromelanin) compared to the
level of B3GALT4 gene expression that could be observed in neurons in the same section located outside of the SN (D).
Scale = 25 μm for each.
https://doi.org/10.1371/journal.pone.0199189.g005
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with the endogenous membrane-bound sialidase that converts GD1a into GM1[22]. A
decrease in expression of B3GALT4 and ST3GAL2 genes, as currently observed in residual
dopaminergic neurons in the PD SN, is expected to have a major impact on both GM1 and
GD1a levels (as well as GD1b and GQ1b levels), reducing expression of these gangliosides, and
potentially putting the affected neurons at risk. While GM1 is the ganglioside that has been
most studied in relation to PD, due to its putative neuroprotective/neurorestorative properties,
it is not clear at this time the extent to which decreased levels of GD1a, GD1b and GQ1b may
also contribute to the neurodegeneration of dopaminergic neurons in PD.
Treatment with GM1 following different types of lesions [ex., [24–26]], including in animal
models of PD [ex., [27–35], results in significant biochemical and behavioral recovery. In PD
models, GM1 administration rescued damaged SN pars compacta dopamine (DA) neurons
and increased striatal DA levels in mouse and non-human primate PD animal models [27–
35]. Positive effects of GM1 administration on PD animal models has also translated to the
clinic, where positive effects of GM1 treatment have been observed in PD patients [36–39].
In our double-blind placebo controlled delayed start study of GM1 in PD [38], we found
that GM1 administration had a relatively early appearing symptomatic effect (similar to what
we had described in a previous short duration double blind study [36]), however, with long-
term use, we showed for the first time clinical evidence that GM1 administration could poten-
tially slow PD symptom progression [38]. This study provided clinical proof-of-concept data,
consistent with many pre-clinical findings, that GM1 use could potentially protect dopamine
(DA) neurons from dying and/or rescue and restore functionality to damaged DA neurons
leading to a lower than expected rate of symptom progression in PD patients. The reasons for
the efficacy of GM1 in the clinical studies mentioned above are still not completely under-
stood. However, based on our current findings, we hypothesize that due to downregulation of
B3GALT4 and ST3GAL2 genes in DAergic neurons, there is decreased expression of GM1 and
other major brain gangliosides in PD SN that could increase the vulnerability of these DA neu-
rons to damage. The reasons for these gene expression changes in PD are not known and may
represent a fundamental defect leading to the development of PD or may represent a response
of these neurons to some toxin or stressor that initiates the disease process. Nonetheless, we
suggest that administration of GM1 in the clinical studies mentioned above replaced a critical
amount of GM1 lost in the disease and allowed incorporation of sufficient amounts of GM1
into SN DA neurons to enhance functionality and stabilize/protect these neurons.
Recent studies have reported that mice with knockout of the B4Galnt1 gene have loss of a-
and b-series gangliosides including GM1, and develop a progressive parkinsonism [18, 19].
We did not examine B4GALNT1 gene expression in the current study so we cannot exclude
the possibility that there may also be decreased expression of this gene as well. However, since
we previously did not observe a decrease in GM2 or GD2 levels in PD SN [20], we do not
think that a decrease in B4GALNT1 gene expression was likely. It has also been reported that
there were diminished levels of GM1 and GD1a in occipital cortex from PD brains, suggesting
the possibility of a more widespread deficiency in ganglioside expression beyond the SN [19].
Although we did not examine brain regions other than the SN in the current study, we did
observe high levels of B3GALT4 and ST3GAL2 gene expression in non-DAergic neurons out-
side of the SN in the PD brain, in the same sections in which decreased gene expression was
observed in SN neuromelanin-containing neurons. This observation suggests that the gene
expression changes observed in the PD brain may be specific to SN DAergic neurons. The dis-
crepancy between this and the findings reported previously [19] are unclear and require fur-
ther research to understand.
Currently, the precise role of alterations in ganglioside expression in the degeneration of
DAergic neurons in PD is not known, nor is it entirely clear why there is decreased expression
Ganglioside-related gene expression in PD
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of B3GALT4 and ST3GAL2 mRNAs in remaining dopaminergic neurons in the PD SN and
what this means for the health and survival of these neurons. It is also not known what poten-
tial triggers might underlie disrupted ganglioside biosynthesis and expression in PD nor is
there any direct information at this time that relates such occurrences to the vulnerability and/
or degeneration of DA neurons. However, it is intriguing to hypothesize that intrinsic or
acquired defects in ganglioside biosynthesis may lead to altered ganglioside levels which, even
with a relatively small reduction in GM1 expression, may contribute to heightened susceptibil-
ity of DA neurons to potentially damaging cellular stressors and over time, lead to the neuro-
degeneration characteristic of PD.
Conclusions
In summary, residual neuromelanin-containing neurons in the PD SN were found to have
decreased expression of the ganglioside biosynthetic genes B3GALT4 and ST3GAL2, consistent
with findings of decreased levels of gangliosides GM1, GD1a, GD1b and GT1b in the PD SN
[20]. The decreased expression of these genes and the resulting decreases in major brain gan-
gliosides, including GM1, likely increases the vulnerability of these neurons to degeneration in
response to a variety of potential stressors. It has been hypothesized that neurodegeneration in
PD due to decreased GM1 levels is due at least in part to a failure in trophic signaling (particu-
larly GDNF signaling) [19, 40] and that this GM1-related failure of trophic signaling leads to
depressed clearance of and accumulation of alpha-synuclein [19, 40]. Along these lines, recent
studies have demonstrated the inhibition of alpha-synuclein aggregation through the interac-
tion of the protein with GM1 [41] and these authors suggested that the presence of GM1 may
moderate synuclein-dependent neuronal dysfunction [41]. Together, the current and other
findings support an important role of GM1 in the pathogenesis of PD and the continued study
of GM1 replacement as an effective therapeutic strategy for the treatment of PD.
Supporting information
S1 Fig. Representative evidence of intact RNA in post mortem samples. In situ hybridiza-
tion for human Cyclophilin B (PPIB), positive control (A) and dapB, negative control (B) in a
normal case and PPIB (C) and dapB (D) in situ hybridization in a Parkinson’s disease case.
The abundance of red dots in the positive control signifies RNA of sufficient quality for study
of the target RNAs. The absence of signal in the negative control demonstrates the specificity
of the in situ reaction. Scale = 25 μm.
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